Useful resources |
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients (Cochrane Review) ABSTRACT Background: Target of rapamycin inhibitors (TOR-I) (sirolimus, everolimus) are immunosuppressive agents with a novel mode of action but an uncertain clinical role. |
Full article: The full article is available on Wiley InterScience at http://www.thecochranelibrary.com |